Significance of lymphovascular invasion in organ‐confined, node‐negative urothelial cancer of the bladder: data from the prospective p53‐ MVAC trial
Year: 2014
Type: article
Abstract: OBJECTIVES: To investigate the association between lymphovascular invasion (LVI) and clinical outcome in organ-confined, node-negative urothelial cancer of the bladder (UCB) in a post hoc analysis of a prospective clinical trial. To explore the effect of adjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) on outcome in the subset of patients whose tumours exhibited LVI. PATIENTS AND METHODS: Surgical and tumour factors were extracted from the operative and pathology reports of 499 patients who had undergone radical cystectomy (RC) for pT1-T2 N0 UCB in the p53-MVAC trial (Southwest Oncology Group 4B951/NCT00005047). The presence or absence of LVI was determined by pathological examination of transurethral resection or RC specimens. Variables were examined in univariate and multivariate Cox proportional hazards models for associations with time to recurrence (TTR) and overall survival (OS). RESULTS: Among 499 patients with a median follow-up of 4.9 years, a subset of 102 (20%) had LVI-positive tumours. Of these, 34 patients had pT1 and 68 had pT2 disease. LVI was significantly associated with TTR with a hazard ratio (HR) of 1.78 [95% confidence interval (CI) 1.15-2.77; number of events (EV) 95; P = 0.01) and with OS with a HR of 2.02 (95% CI 1.31-3.11; EV 98; P = 0.001) after adjustment for pathological stage. Among 27 patients with LVI-positive tumours who were randomised to receive adjuvant chemotherapy, receiving MVAC was not significantly associated with TTR (HR 0.70, 95% CI 0.16-3.17; EV 7; P = 0.65) or with OS (HR 0.45, 95% CI 0.11-1.83; EV 9; P = 0.26). CONCLUSIONS: Our post hoc analysis of the p53-MVAC trial revealed an association between LVI and shorter TTR and OS in patients with pT1-T2N0 disease. The analysis did not show a statistically significant benefit of adjuvant MVAC chemotherapy in patients with LVI, although a possible benefit was not excluded.
Source: British Journal of Urology
DOI: 10.1111/bju.12997
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G1033243903, G1347238333, G1548551769, G1688026025, G1790576020, G1843195030, G2345882982, G3337849518, City of Hope Southwest Oncology Group Clinical Trials, G3650305600, NCI National Clinical Trials Network-Network Lead Academic Participating Site, SWOG Network Group Operations Center of the NCTN, G3939550896, G4289044101, G4468683055, G4768276527, G5245746260, NCI NCTN- Network Lead Academic Participating Site: USC, G5726269583, G5876287064, Southwest Oncology Group, MCAV in Organ-Confined Bladder CA based on p53 Status, ESTROGEN RECEPTOR TARGETED TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER, G6970698343, Virginia Mason Community Clinical Oncology Program, MOLECULAR/CELLULAR PATHWAYS OF BLADDER CA++ PROGRESSION, G8231620523, University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG)
OpenAlex ID: W2020531505